DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2

• Basic technology involves promising single-domain antibodies simultaneously targeting two surface structures of the viral spike protein.
• The main candidates of DIOS-202 and DIOS-203 are engineered for high capacity and the ability to avoid the emergence of escape mutants.
• DIOS-202 and DIOS-203 went into accelerated development to begin clinical trials later this year.

BONN, Germany, January 12, 2021 – DiosCURE SE announced publication in Science describes its main technology of multicellular single-chain antibodies with a specific molecular mode of action to activate SARS-CoV-2 virions. Developed and identified an international team led by scientists at the University of Bonn the main candidates, which is approved only by DiosCURE.

“This global pandemic requires an arsenal of therapeutic and protective devices and the key candidates will allow us to contribute to what will be an ongoing battle,” said Klaus Wilgenbus, Chief Executive Officer of DiosCURE. developing novel, best-in-class immunotherapies to protect large populations that remain at risk, including open healthcare workers, immunocompromised patients, non-responders to vaccines and patients who suffers from post-hunger COVID-19. syndrome. The published data now provides a strong basis for continuing our development efforts with the aim of entering the clinic later this year. “

The company’s main candidates, DIOS-202 and DIOS-203, are a synergistic combination of single-domain antibodies derived exclusively from heavy-chain camelid antibodies. The next-generation immunotherapies against SARS-CoV-2 were designed based on detailed structural information about the interaction of the antibodies with its viral target protein and are the result of functional and evolutionary experiments. The discovery and promising early data were published in an article in Science titled “Structure-driven multimodal nanobodies prevent SARS-CoV-2 infection and eliminate mutational escape” on January 12, 2021. The study details has identified key DiosCURE candidates out of millions of potential structures, as well as a rational design of a multifaceted construction, which increased neutral activity more than 100-fold. Preclinical studies have shown that DIOS-202 and DIOS-203 selectively target two specific epitopes of SARS-CoV-2 spike proteins simultaneously, which largely inhibit escape mutants. The dual targeting promotes the premature activation of the fusion device, rendering the viruses non-infectious. These discoveries were achieved through a collaborative effort of research groups at Bonn University Hospital (led by the Institute of Indigenous Immunology and Basic Resource Nanobodies), the Scripps Research Institute and the Karolinska Institute.

The main candidates are expected to be highly efficient, well tolerated, cost effective in production and accessible to a wide range of clinical applications. As immunotherapies, DIOS-202 and DIOS-203 are suitable both as prophylactic and for the treatment of infected patients to avoid severe COVID-19 infection.

“The structure-based multi-chain antibodies we have found have strong potency for clinical applications. This is due to their strong neutralizing activity and internal protection from the rapid emergence of escaped mutants. escape of SARS-CoV-2 Mutants will remain an ongoing challenge in this pandemic, and novel therapies are urgently needed to address this problem, “said Eicke Latz, Director of the Institute of Indigenous Immunity at the University of Bonn , co-founder and Board member of DiosCURE. “Our understanding of the short-term and long-term effects of SARS-CoV-2 is rapidly evolving, and reasonable treatment aimed at the virus is needed to prevent the devastating effects. which COVID-19 may have. “

###

In DiosCURE

DiosCURE is developing next-generation immunotherapies with a focus on a new approach against SARS-CoV-2. Variable fields of bilateral and trivalent properties of heavy-chain antibodies only (VHHs) are a synergistic combination of single-domain antibodies, built after structural information and elevated for strength in addition to their ability to avoid the emergence of escape mutants. DiosCURE designed key candidates targeting two different epitopes of SARS-CoV-2 spike proteins with the ability to be highly efficient, well tolerated and manufactured at a large-scale conventional process. To learn more about our company, visit http: // www.DiosCURE.com

Contact DiosCURE:

Klaus Wilgenbus, MD

Chief Executive

[email protected]

Contact the media:

Trophic communication

Eva Mulder and Sophia Hergenhan, Ph.D.

[email protected]

+49 89 238 877 30